Company Description
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.
The company’s lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck.
It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3.
The company was founded in 2007 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2007 |
| IPO Date | Dec 16, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 61 |
| CEO | Jay Short |
Contact Details
Address: 11085 Torreyana Road San Diego, California 92121 United States | |
| Phone | 858 558 0708 |
| Website | bioatla.com |
Stock Details
| Ticker Symbol | BCAB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001826892 |
| CUSIP Number | 09077B104 |
| ISIN Number | US09077B1044 |
| Employer ID | 85-1922320 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jay M. Short Ph.D. | Co-Founder, Chief Executive Officer and Chairman |
| Richard A. Waldron | Senior Vice President and Chief Financial Officer |
| Dr. Eric L. Sievers M.D. | Chief Medical Officer |
| Christian J. Vasquez CPA | Chief Accounting Officer, Controller and Corporate Secretary |
| Susie Melody | Senior Vice President of Human Resources |
| Dr. Cathy Chang Ph.D. | Senior Vice President of Research and Development |
| Dr. Gerhard Frey Ph.D. | Senior Vice President of Technology Development |
| Monica Sullivan | Senior Vice President of Intellectual Property and Contracts |
| Sheri Lydick | Chief Commercial Officer |
| Lisa M. Pelton | Accounting Manager |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 20, 2025 | 8-K | Current Report |
| May 20, 2025 | SCHEDULE 13G/A | Filing |
| May 16, 2025 | 8-K | Current Report |
| May 16, 2025 | 424B3 | Prospectus |
| May 14, 2025 | EFFECT | Notice of Effectiveness |
| May 9, 2025 | UPLOAD | Filing |
| May 6, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| May 6, 2025 | 10-Q | Quarterly Report |
| May 6, 2025 | 8-K | Current Report |
| Apr 25, 2025 | SCHEDULE 13G/A | Filing |